The widespread adoption of GLP-1 receptor agonists is creating fiscal pressures for commercial healthcare plans, necessitating new risk-sharing strategies with pharmaceutical manufacturers.
Budgetary Strain on Payers
Annual prescription costs for GLP-1 therapies threaten to escalate overall pharmacy benefit expenditures, forcing insurers to tighten prior authorization requirements and coverage guidelines.
Outcome-Based Contracting
To manage financial exposure, major health plans are negotiating outcome-based pricing models that tie drug reimbursement rates to measurable, long-term health improvements in patient cohorts.